Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese mice
Metabolic inflammation mediated by the hepatocytic IL-1 receptor type 1 is a cofactor in mutagenic hepatocarcinogenesis. Targeting IL-1 signaling could be an adjunct strategy to the current immunomodulatory HCC treatments.
Authors
- Beate Katharina Straub (ORCID: https://orcid.org/0000-0002-4857-1561)
- Ari Waisman (ORCID: https://orcid.org/0000-0003-4304-8234)
- Leonard Kaps (ORCID: https://orcid.org/0000-0002-4782-8003)
- Peter R. Galle (ORCID: https://orcid.org/0000-0001-8294-0992)
- Nadine Gehrke (ORCID: https://orcid.org/0000-0002-4731-0183)
- Lea J. Hofmann
- Jörn M. Schattenberg (ORCID: https://orcid.org/0000-0002-4224-4703)
- Dirk A. Ridder
Institutions
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Saarland University (DE)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1097/hc9.0000000000000568
- Citations
- 7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Gilead Sciences
- European Commission
- Bayer HealthCare
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz